2.1. Study Design and Participants
cancers, colorectal, prostatic, endometrial, and female, breast cancers, renal cancer, cancer, weight loss, DUET, Cancer
CANCERS, RENAL CANCER, CANCER, SECONDARY, CANCER
A secondary analysis was performed using baseline and 6-month follow-up data from the DUET intervention, a 2-arm, single-blinded, randomized controlled trial (RCT) in which 112 cancer survivors and their partners (56 dyads) were assigned to either a 6-month web-based diet and exercise, weight loss intervention or a wait-list control. The study was approved by the University of Alabama at Birmingham (UAB) Institutional Review Board (IRB# 300003882) and registered with ClinicalTrials.gov (NCT04132219). All participants in the study provided written informed consent. Data collection started in October 2020 and ended in December 2021. The methods and primary outcomes of the DUET trial are published in detail elsewhere [Cancer survivors were ascertained through a combination of cancer registries, self-referral networks, and previously established lists of interested cancer survivors who were diagnosed and completed treatment for obesity-related cancers that have a 5-year survival rate of ≥70% (i.e., localized renal cancer and loco-regional ovarian, colorectal, prostatic, endometrial, and female breast cancers). These individuals were telephoned and screened by the study staff. The eligibility criteria for the DUET study were as follows: (1) BMI > 25 kg/m